MDV3100 for the treatment of prostate cancer.

Abstract

INTRODUCTION:

MDV3100 is a rationally designed androgen receptor antagonist, which has recently been shown to improve survival in men with metastatic castration-resistant prostate cancer previously treated with docetaxel chemotherapy. Drug development for advanced prostate cancer is advancing at a rapid pace with four other novel therapies (abiraterone, cabazitaxel, alpharadin and sipuleucel-T) also shown to improve overall survival in large randomised studies.

AREAS COVERED:

This review will cover the historical background of androgen deprivation therapy, recently approved agents for advanced prostate cancer, an overview of the clinical development of MDV3100 and an analysis of how MDV3100 may fit into future treatment protocols for this disease.

EXPERT OPINION:

Full analysis of safety and efficacy data is awaited; however, MDV3100 appears to be a well-tolerated addition to the expanding portfolio of effective drugs for the treatment of advanced prostate cancer.

• Authors: Deborah Mukherji, Carmel J Pezaro, Johann S De-Bono
• Journal: Expert opinion on investigational drugs (Expert Opin Investig Drugs) Vol. 21 Issue 2 Pg. 227-33 (Feb 2012) ISSN: 1744-7658 [Electronic] England
• PMID: 22229405 (Publication Type: Journal Article, Review)

Chemical References

• Androgen Receptor Antagonists
• Antineoplastic Agents
• Benzamides
• Nitriles
• Phenylthiohydantoin
• enzalutamide

Topics

• Androgen Receptor Antagonists (therapeutic use)
• Antineoplastic Agents (therapeutic use)
• Benzamides
• Humans
• Male
• Nitriles
• Phenylthiohydantoin (analogs & derivatives, therapeutic use)
• Prostatic Neoplasms (drug therapy)